Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Tarasov Website

Sergey G. Tarasov, Ph.D.

Selected Publications

1)  Das R, Liang YH, Mariano J, Li J, Huang T, King A, Tarasov SG, Weissman AM, Ji X, Byrd RA.
Allosteric regulation of E2:E3 interactions promote a processive ubiquitination machine.
EMBO J. 32: 2504-16, 2013.
2)  Khavrutskii L, Yeh J, Timofeeva O, Tarasov SG, Pritt S, Stefanisko K, Tarasova N.
Protein purification-free method of binding affinity determination by microscale thermophoresis.
J Vis Exp. 2013.
3)  Tewary P, de la Rosa G, Sharma N, Rodriguez LG, Tarasov SG, Howard OM, Shirota H, Steinhagen F, Klinman DM, Yang D, Oppenheim JJ.
ß-Defensin 2 and 3 Promote the Uptake of Self or CpG DNA, Enhance IFN-a Production by Human Plasmacytoid Dendritic Cells, and Promote Inflammation.
J. Immunol. 191: 865-74, 2013.
4)  Timofeeva OA, Chasovskikh S, Lonskaya I, Tarasova NI, Khavrutskii L, Tarasov SG, Zhang X, Korostyshevskiy VR, Cheema A, Zhang L, Dakshanamurthy S, Brown ML, Dritschilo A.
Mechanisms of Unphosphorylated STAT3 Transcription Factor Binding to DNA.
J. Biol. Chem. 287: 14192-200, 2012.
5)  Liu S, Chen Y, Li J, Huang T, Tarasov S, King A, Weissman AM, Byrd RA, Das R.
Promiscuous interactions of gp78 E3 ligase CUE domain with polyubiquitin chains.
Structure. 20: 2138-50, 2012.
6)  Johannessen L, Remsberg J, Gaponenko V, Adams KM, Barchi JJ, Tarasov SG, Jiang S, Tarasova NI.
Peptide structure stabilization by membrane anchoring and its general applicability to the development of potent cell-permeable inhibitors.
Chembiochem. 12: 914-21, 2011.
7)  Stagno JR, Altieri AS, Bubunenko M, Tarasov SG, Li J, Court DL, Byrd RA, Ji X.
Structural basis for RNA recognition by NusB and NusE in the initiation of transcription antitermination.
Nucleic Acids Res. 39: 7803-15, 2011.
8)  Tarasov SG, Gaponenko V, Howard OM, Chen Y, Oppenheim JJ, Dyba MA, Subramaniam S, Lee Y, Michejda C, Tarasova NI.
Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles.
Proc. Natl. Acad. Sci. U.S.A. 108: 9798-803, 2011.
9)  Tu C, Zhou X, Tarasov SG, Tropea JE, Austin BP, Waugh DS, Court DL, Ji X.
The Era GTPase recognizes the GAUCACCUCC sequence and binds helix 45 near the 3' end of 16S rRNA.
Proc. Natl. Acad. Sci. U.S.A. 108: 10156-61, 2011.
10)  Li C, Pazgier M, Li J, Li C, Liu M, Zou G, Li Z, Chen J, Tarasov SG, Lu WY, Lu W.
Limitations of peptide retro-inverso isomerization in molecular mimicry.
J. Biol. Chem. 285: 19572-81, 2010.
11)  Das R, Mariano J, Tsai YC, Kalathur RC, Kostova Z, Li J, Tarasov SG, McFeeters RL, Altieri AS, Ji X, Byrd RA, Weissman AM.
Allosteric activation of E2-RING finger-mediated ubiquitylation by a structurally defined specific E2-binding region of gp78.
Mol. Cell. 34: 674-85, 2009.
12)  Yavlovich A, Singh A, Tarasov S, Capala J, Blumenthal R, Puri A.
J Therm Anal Calorim. 98: 97-104, 2009.
13)  Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS.
Engineered human antibody constant domains with increased stability.
J. Biol. Chem. 284(21): 14203-10, 2009.
14)  Acchione M, Lipschultz CA, Desantis ME, Shanmuganathan A, Li M, Wlodawer A, Tarasov S, Smith-Gill SJ.
Light chain somatic mutations change thermodynamics of binding and water coordination in the HyHEL-10 family of antibodies.
Mol. Immunol. 47: 457-64, 2009.
15)  Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C, Li J, Monbo J, Zella D, Tarasov SG, Lu W.
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Proc. Natl. Acad. Sci. U.S.A. 106: 4665-70, 2009.
16)  Das R, Loss S, Li J, Waugh DS, Tarasov S, Wingfield PT, Byrd RA, Altieri AS.
Structural biophysics of the NusB:NusE antitermination complex.
J. Mol. Biol. 376: 705-20, 2008.
17)  Datta SA, Zhao Z, Clark PK, Tarasov S, Alexandratos JN, Campbell SJ, Kvaratskhelia M, Lebowitz J, Rein A.
Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switch.
J. Mol. Biol. 365: 799-811, 2007.
18)  Timofeeva OA, Gaponenko V, Lockett SJ, Tarasov SG, Jiang S, Michejda CJ, Perantoni AO, Tarasova NI.
Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target.
ACS Chem. Biol. 2: 799-809, 2007.
19)  Remsberg JR, Lou H, Tarasov SG, Dean M, Tarasova NI.
Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth.
J. Med. Chem. 50: 4534-8, 2007.
20)  Tarasova NI, Seth R, Tarasov SG, Kosakowska-Cholody T, Hrycyna CA, Gottesman MM, Michejda CJ.
Transmembrane inhibitors of P-glycoprotein, an ABC transporter.
J Med Chem. 48: 3768-75, 2005.
21)  Yu P, Neamati N, Tarasov S, He Q, Sheikh MS, Wang YX.
Codon-optimized cloning, expression and characertization of the C-terminal region of human apoptotic protein GADD34 in Escherichia coli.
Cell Cycle. 3: 75-9, 2004.
22)  Tarasov SG, Casas-Finet JR, Cholody WM, Kosakowska-Cholody T, Gryczynski ZK, Michejda CJ.
Bisimidazoacridones: 2. Steady-state and time-resolved fluorescence studies of their diverse interactions with DNA.
Photochem Photobiol. 78: 313-22, 2003.
23)  Hofmann A, Tarasov S, Grella M, Ruvinov S, Nasr F, Filipowicz W, Wlodawer A.
Biophysical characterization of cyclic nucleotide phosphodiesterases.
Biochem Biophys Res Commun. 291: 875-83, 2002.
24)  Tarasov SG, Casas-Finet JR, Cholody WM, Michejda CJ.
Bisimidazoacridones: effect of molecular environment on conformation and photophysical properties.
Photochem Photobiol. 70: 568-78, 1999.
Click Here to View Collapsed Bibliography.

This page was last updated on 11/19/2013.